Compare Stocks: LPCN, ELOX, ATHE, and TENX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$3.75 +5.5%	$4.45	$2.66 ▼ $5.89	$67.88M	0.27	26,087 shs	1,444 shs
ELOX Eloxx Pharmaceuticals	$16.70 +8.2%	$16.20	$8.20 ▼ $23.40	$67.47M	-1862.26	49,873 shs	6,914 shs
LPCN Lipocine	$2.13 +0.7%	$2.18	$1.81 ▼ $12.37	$17.58M	0.47	190,834 shs	11,679 shs
TENX Tenax Therapeutics	$1.85 -2.9%	$6.23	$1.31 ▼ $19.40	$69.04M	0.83	2.22 million shs	1.02 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	-6.08%	-4.93%	-22.32%	-27.55%	-20.40%
ELOX Eloxx Pharmaceuticals	-7.71%	-12.42%	-22.76%	+31.40%	+127,503.31%
LPCN Lipocine	-1.85%	-1.85%	+2.91%	-10.92%	-23.19%
TENX Tenax Therapeutics	-2.06%	+4.40%	+2.70%	-85.26%	-70.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$3.75 +5.5%	$4.45	$2.66 ▼ $5.89	$67.88M	0.27	26,087 shs	1,444 shs
ELOX Eloxx Pharmaceuticals	$16.70 +8.2%	$16.20	$8.20 ▼ $23.40	$67.47M	-1862.26	49,873 shs	6,914 shs
LPCN Lipocine	$2.13 +0.7%	$2.18	$1.81 ▼ $12.37	$17.58M	0.47	190,834 shs	11,679 shs
TENX Tenax Therapeutics	$1.85 -2.9%	$6.23	$1.31 ▼ $19.40	$69.04M	0.83	2.22 million shs	1.02 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	-6.08%	-4.93%	-22.32%	-27.55%	-20.40%
ELOX Eloxx Pharmaceuticals	-7.71%	-12.42%	-22.76%	+31.40%	+127,503.31%
LPCN Lipocine	-1.85%	-1.85%	+2.91%	-10.92%	-23.19%
TENX Tenax Therapeutics	-2.06%	+4.40%	+2.70%	-85.26%	-70.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.57	Moderate Buy	$10.00	163.30% Upside
ELOX Eloxx Pharmaceuticals	3.00	Buy	$38.33	131.76% Upside
LPCN Lipocine	2.00	Hold	$4.00	90.02% Upside
TENX Tenax Therapeutics	2.40	Hold	$14.00	654.72% Upside

Current Analyst Ratings Breakdown

Latest LPCN, ELOX, ATHE, and TENX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	LPCN Lipocine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/21/2026	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$4.00
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$32.00
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy	$32.00
9/15/2026	ATHE Alterity Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/15/2026	ATHE Alterity Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/14/2026	TENX Tenax Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	TENX Tenax Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/3/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	TENX Tenax Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral
8/31/2026	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.60 per share	N/A
ELOX Eloxx Pharmaceuticals	$6.36M	10.51	N/A	N/A	($85.17) per share	-0.19
LPCN Lipocine	$1.98M	8.76	N/A	N/A	$2.61 per share	0.81
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$10.42 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$15.88M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	-$5.99M	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	-$9.63M	-$1.79	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	11/5/2026 (Estimated)
TENX Tenax Therapeutics	-$52.60M	-$1.48	N/A	N/A	N/A	N/A	-61.54%	-57.42%	11/11/2026 (Estimated)

Latest LPCN, ELOX, ATHE, and TENX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million
7/31/2026	Q2 2026	TENX Tenax Therapeutics	-$0.3813	-$0.35	+$0.0313	-$0.35	N/A	N/A
7/30/2026	Q4 2026 TU	ATHE Alterity Therapeutics	N/A	-$0.28	N/A	-$0.28	N/A	$0.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	14.52	14.52
ELOX Eloxx Pharmaceuticals	N/A	3.74	3.74
LPCN Lipocine	N/A	11.48	11.48
TENX Tenax Therapeutics	N/A	15.07	15.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
ELOX Eloxx Pharmaceuticals	2.90%
LPCN Lipocine	9.11%
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
ELOX Eloxx Pharmaceuticals	25.90%
LPCN Lipocine	4.69%
TENX Tenax Therapeutics	10.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	11	18.13 million	11.09 million	Not Optionable
ELOX Eloxx Pharmaceuticals	7	4.04 million	2.99 million	N/A
LPCN Lipocine	14	8.24 million	7.86 million	No Data
TENX Tenax Therapeutics	16	37.42 million	33.38 million	Not Optionable

LPCN, ELOX, ATHE, and TENX Headlines

Recent News About These Companies

Tenax Therapeutics (NASDAQ:TENX) Director Declan Doogan Purchases 53,000 Shares of Stock

September 18, 2026 | insidertrades.com

Declan Doogan Purchases 53,000 Shares of Tenax Therapeutics (NASDAQ:TENX) Stock

September 17, 2026 | marketbeat.com

Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Update

September 16, 2026 | marketbeat.com

Piper Sandler Remains a Buy on Tenax Therapeutics (TENX)

September 16, 2026 | theglobeandmail.com

Tenax Therapeutics (NASDAQ:TENX) CEO Acquires $11,280.00 in Stock

September 16, 2026 | insidertrades.com

Tenax Therapeutics (NASDAQ:TENX) CEO Christopher Thomas Giordano Buys 6,000 Shares

September 15, 2026 | marketbeat.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Buys $1,602,000.00 in Stock

September 9, 2026 | insidertrades.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Adar1 Capital Management, Llc Purchases 900,000 Shares of Stock

September 8, 2026 | marketbeat.com

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

September 4, 2026 | insidermonkey.com

Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of "Hold" by Brokerages

September 4, 2026 | marketbeat.com

Insider Buying: Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Purchases $322,304.40 in Stock

September 3, 2026 | insidertrades.com

Braidwell LP Acquires New Holdings in Tenax Therapeutics, Inc. $TENX

September 3, 2026 | marketbeat.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Purchases 179,058 Shares of Stock

September 2, 2026 | marketbeat.com

Adar1 Capital Management, Llc Purchases 187,704 Shares of Tenax Therapeutics (NASDAQ:TENX) Stock

September 2, 2026 | marketbeat.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Adar1 Capital Management, Llc Buys 403,571 Shares

September 2, 2026 | marketbeat.com

Guggenheim downgrades Tenax Therapeutics (TENX)

September 2, 2026 | msn.com

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026 | globenewswire.com

Tenax's Phase 3 Study For TNX-103 Fails To Meet Primary Endpoint; Shows Success In Other Measures

August 30, 2026 | rttnews.com

Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss

August 30, 2026 | seekingalpha.com

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

August 29, 2026 | quiverquant.comQ

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

August 29, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LPCN, ELOX, ATHE, and TENX Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$3.74 +0.20 (+5.49%)

As of 11:23 AM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Eloxx Pharmaceuticals NASDAQ:ELOX

$16.70 +1.26 (+8.16%)

As of 11:08 AM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Lipocine NASDAQ:LPCN

$2.13 +0.01 (+0.66%)

As of 11:30 AM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Tenax Therapeutics NASDAQ:TENX

$1.84 -0.06 (-2.89%)

As of 11:31 AM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LPCN, ELOX, ATHE, and TENX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LPCN, ELOX, ATHE, and TENX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LPCN, ELOX, ATHE, and TENX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LPCN, ELOX, ATHE, and TENX Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

Eloxx Pharmaceuticals NASDAQ:ELOX

Lipocine NASDAQ:LPCN

Tenax Therapeutics NASDAQ:TENX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LPCN, ELOX, ATHE, and TENX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LPCN, ELOX, ATHE, and TENX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LPCN, ELOX, ATHE, and TENX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LPCN, ELOX, ATHE, and TENX Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

Eloxx Pharmaceuticals NASDAQ:ELOX

Lipocine NASDAQ:LPCN

Tenax Therapeutics NASDAQ:TENX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools